U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07364396) titled 'Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus' on Aug. 20, 2025.
Brief Summary: The purpose of this clinical trial is to evaluate the safety and efficacy of CRC01, an investigational autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, in people with lupus nephritis (LN), a serious kidney complication of systemic lupus erythematosus (SLE).
The main objectives of the study are:
1. To determine whether CRC01 infusion can improve kidney outcomes and reduce disease activity in participants with lupus nephritis.
2. To assess the safety profile, including potential r...